Moderna aims to top list of 5 largest biotech IPOs ever

Shutterstock photo

Moderna ( MRNA ) is scheduled to raise $500 million tonight at an $8.0 billion valuation. On both measures, that would make it the largest development-stage drug developer ever to go public.

Below we present the five largest biotech IPOs by deal size.

Our premium IPO Pro platform lets you screen for every 2018 healthcare IPO,  then dig down into the biotechs. 

Start a Free Trial of IPO Pro

After Moderna, the past four largest biotech IPOs generated a lot of hype at the time of their offerings and had a strong gain on day one. Three traded up from there, while Axovant's -88% return highlights the risk of awarding $1+ billion valuation to biotechs.

5 Largest Biotech IPOs of All Time, by Deal Size
Market Cap
at IPO
First Day
at 12/05
Moderna ( MRNA )$500M$8,016M12/07/18 - -
Allogene Therapeutics ( ALLO )$324M$2,188M10/11/18 39%  74%
Axovant Sciences ( AXON )$315M$1,504M06/11/15 99% -88%
Galapagos ( GLPG )$275M$1,659M05/14/15 20% 140%
Juno Therapeutics (JUNO)$265M$2,164M12/19/14 46%262%*

*Return from IPO to Jan 2018 acquisition 

The article Moderna aims to top list of 5 largest biotech IPOs ever originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs
Referenced Symbols: MRNA , ALLO , AXON , GLPG

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?